Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Viewpoint
  • Published:

Breaking frontiers with multidisciplinary cancer research

Nature Cancer volume 6, pages 13–15 (2025)Cite this article

Five experts share their thoughts on key areas of focus in multidisciplinary cancer research for the upcoming years. They discuss the research approaches, tools, technologies, collaborations and way of thinking the lab of the future should integrate.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Department of Clinical Biochemistry, University of Cambridge, Cambridge, UK

    Carlos Caldas

  2. Department of Diagnostic Radiology, Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore, Singapore, Singapore

    Xiaoyuan Chen

  3. Department of Surgery, Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore, Singapore, Singapore

    Xiaoyuan Chen

  4. Department Chemical and Biomolecular Engineering, Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore, Singapore, Singapore

    Xiaoyuan Chen

  5. Department of Biomedical Engineering, Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore, Singapore, Singapore

    Xiaoyuan Chen

  6. Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

    Xiaoyuan Chen

  7. Nanomedicine Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

    Xiaoyuan Chen

  8. Theranostics Center of Excellence, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

    Xiaoyuan Chen

  9. Institute of Molecular and Cell Biology, Agency for Science, Technology, and Research (A*STAR), Singapore, Singapore

    Xiaoyuan Chen

  10. Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA

    Li Ding

  11. McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA

    Li Ding

  12. Department of Genetics, Washington University in St. Louis, St. Louis, MO, USA

    Li Ding

  13. Else Kroener Fresenius Center for Digital Health, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany

    Jakob Nikolas Kather

  14. Department of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany

    Jakob Nikolas Kather

  15. Medical Oncology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany

    Jakob Nikolas Kather

  16. AstraZeneca, Gaithersburg, MD, USA

    Maurizio Scaltriti

Authors
  1. Carlos Caldas
    View author publications

    Search author on:PubMed Google Scholar

  2. Xiaoyuan Chen
    View author publications

    Search author on:PubMed Google Scholar

  3. Li Ding
    View author publications

    Search author on:PubMed Google Scholar

  4. Jakob Nikolas Kather
    View author publications

    Search author on:PubMed Google Scholar

  5. Maurizio Scaltriti
    View author publications

    Search author on:PubMed Google Scholar

Corresponding authors

Correspondence to Carlos Caldas, Xiaoyuan Chen, Li Ding, Jakob Nikolas Kather or Maurizio Scaltriti.

Ethics declarations

Competing interests

X.C. is a co-founder of and holds shares in Yantai Lannacheng Biotechnology. J.N.K. declares consulting services for Bioptimus, Owkin, DoMore Diagnostics, Panakeia, AstraZeneca, Scailyte, Mindpeak and MultiplexDx. Furthermore, he holds shares in StratifAI GmbH, and Synagen GmbH; has received a research grant from GSK; and has received honoraria from AstraZeneca, Bayer, Daiichi Sankyo, Eisai, Janssen, MSD, BMS, Roche, Pfizer and Fresenius. M.S. is an employee and stock holder in AstraZeneca. C.C. and L.D. declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Caldas, C., Chen, X., Ding, L. et al. Breaking frontiers with multidisciplinary cancer research. Nat Cancer 6, 13–15 (2025). https://doi.org/10.1038/s43018-024-00875-1

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s43018-024-00875-1

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing